Biostem Technologies

Biostem Technologies Net Debt

The Net Debt of Biostem Technologies (BSEM) as of Oct 11, 2026 is 150,000.00 USD. In the previous year, Net Debt was 265,635.00 USD — a change of -43.53% (lower).

Net Debt

150,000.00USD

YoY

-43.53%

Last updated:

Net Debt of Biostem Technologies is 2024 150,000.00 USD. Net Debt of Biostem Technologies was 2023 265,635.00 USD. It decreases by -43.53% lower compared to the previous year.

The Biostem Technologies Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
0.00 USD
Jan 1, 2018
467,861.00 USD
Jan 1, 2019
914,349.00 USD
Jan 1, 2020
1.32 M USD
Jan 1, 2021
1.80 M USD
Jan 1, 2022
1.03 M USD
Jan 1, 2023
265,635.00 USD
Jan 1, 2024
150,000.00 USD
The Biostem Technologies Net Debt history
YEARNet DebtYoY
150,000.00USD-43.53%
265,635.00USD-74.12%
1.03 MUSD-42.90%
1.80 MUSD+36.17%
1.32 MUSD+44.39%
914,349.00USD+95.43%
467,861.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
Access this data via the Eulerpool API

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

Net Debt of Biostem Technologies is 150,000.00 USD in 2024.

Net Debt of Biostem Technologies changed from 265,635.00 USD to 150,000.00 USD, representing a -43.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Biostem Technologies historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Biostem Technologies

All Key Metrics — Biostem Technologies